HK1143588A1 - 適合用於治療對血清素 受體調節有反應的病症的多種喹啉化合物 - Google Patents

適合用於治療對血清素 受體調節有反應的病症的多種喹啉化合物

Info

Publication number
HK1143588A1
HK1143588A1 HK10110137.1A HK10110137A HK1143588A1 HK 1143588 A1 HK1143588 A1 HK 1143588A1 HK 10110137 A HK10110137 A HK 10110137A HK 1143588 A1 HK1143588 A1 HK 1143588A1
Authority
HK
Hong Kong
Prior art keywords
serotonin
receptor
respond
modulation
compounds suitable
Prior art date
Application number
HK10110137.1A
Other languages
English (en)
Inventor
Sean Colm Turner
Wilfried Braje
Andreas Haupt
Udo Lange
Karla Drescher
Karsten Wicke
Liliane Unger
Mario Mezler
Matthias Mayrer
Wolfgang Wernet
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of HK1143588A1 publication Critical patent/HK1143588A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK10110137.1A 2007-08-07 2010-10-28 適合用於治療對血清素 受體調節有反應的病症的多種喹啉化合物 HK1143588A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07113962 2007-08-07
PCT/EP2008/060335 WO2009019286A1 (en) 2007-08-07 2008-08-06 Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor

Publications (1)

Publication Number Publication Date
HK1143588A1 true HK1143588A1 (zh) 2011-01-07

Family

ID=39809897

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10110137.1A HK1143588A1 (zh) 2007-08-07 2010-10-28 適合用於治療對血清素 受體調節有反應的病症的多種喹啉化合物

Country Status (23)

Country Link
US (2) US8293913B2 (zh)
EP (1) EP2185555B1 (zh)
JP (1) JP5501230B2 (zh)
KR (1) KR20100039300A (zh)
CN (1) CN101687866B (zh)
AU (1) AU2008285652B2 (zh)
BR (1) BRPI0812853A2 (zh)
CA (1) CA2691529C (zh)
CO (1) CO6251268A2 (zh)
CR (1) CR11187A (zh)
DO (1) DOP2009000291A (zh)
EC (1) ECSP099831A (zh)
ES (1) ES2574154T3 (zh)
GT (1) GT200900333A (zh)
HK (1) HK1143588A1 (zh)
IL (1) IL202706A (zh)
MX (1) MX2009013956A (zh)
NZ (1) NZ581986A (zh)
RU (1) RU2483068C2 (zh)
TW (1) TWI478919B (zh)
UA (1) UA99626C2 (zh)
WO (1) WO2009019286A1 (zh)
ZA (1) ZA200909075B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
KR20160087900A (ko) 2013-11-26 2016-07-22 에프. 호프만-라 로슈 아게 신규한 옥타하이드로-사이클로부타[1,2-c；3,4-c'']다이피롤-2-일
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
EP3882961B1 (en) * 2014-04-30 2023-07-26 Kateeva, Inc. Gas cushion apparatus and techniques for substrate coating
AU2016316717B2 (en) 2015-09-04 2021-02-18 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
EP3353180B1 (en) 2015-09-24 2022-03-16 F. Hoffmann-La Roche AG Bicyclic compounds as atx inhibitors
KR20180053408A (ko) 2015-09-24 2018-05-21 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서의 신규한 이환형 화합물
WO2017050792A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
MX2018001430A (es) 2015-09-24 2018-04-20 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
AR106515A1 (es) * 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
US10160744B2 (en) 2016-03-14 2018-12-25 AbbVie Deutschland GmbH & Co. KG Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-HT6 receptor
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
US20220227773A1 (en) * 2019-05-30 2022-07-21 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Fused ring compound, preparation method therefor and use thereof
TW202317560A (zh) * 2021-06-26 2023-05-01 美商賽迪拉治療股份有限公司 Ｃｄｋ２抑制劑及其使用方法
WO2024140851A1 (zh) * 2022-12-28 2024-07-04 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用
WO2024153165A1 (zh) * 2023-01-18 2024-07-25 苏州旺山旺水生物医药股份有限公司 一种抗抑郁化合物的盐、其制备方法、包含其的药物组合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL186869B1 (pl) * 1995-11-13 2004-03-31 Hoechst Ag Nowe heterocykliczne N-podstawione pochodne kwasów alfa-iminohydroksamowych i karboksylowych, sposób ich wytwarzania, środek farmaceutyczny i ich zastosowanie
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
DE10000739A1 (de) 2000-01-11 2001-07-12 Merck Patent Gmbh Piperidin- und Piperazinderivate
ES2307919T3 (es) * 2002-03-27 2008-12-01 Glaxo Group Limited Derivados de quinolina y su uso como ligandos de 5-ht6.
GB0321473D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) * 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
WO2005042501A1 (en) * 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
DE102004038268A1 (de) * 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0425548D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands
TW200716594A (en) * 2005-04-18 2007-05-01 Neurogen Corp Substituted heteroaryl CB1 antagonists
ATE465151T1 (de) 2005-07-27 2010-05-15 Hoffmann La Roche 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren
GB0519765D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
CO6251268A2 (es) 2011-02-21
CN101687866B (zh) 2014-06-04
JP5501230B2 (ja) 2014-05-21
GT200900333A (es) 2015-10-14
US8293913B2 (en) 2012-10-23
US8440694B2 (en) 2013-05-14
RU2010108282A (ru) 2011-09-20
ECSP099831A (es) 2010-01-29
EP2185555A1 (en) 2010-05-19
AU2008285652A1 (en) 2009-02-12
RU2483068C2 (ru) 2013-05-27
US20130005703A1 (en) 2013-01-03
CR11187A (es) 2010-05-27
BRPI0812853A2 (pt) 2014-12-23
CN101687866A (zh) 2010-03-31
IL202706A (en) 2014-08-31
ES2574154T3 (es) 2016-06-15
IL202706A0 (en) 2010-06-30
TWI478919B (zh) 2015-04-01
UA99626C2 (ru) 2012-09-10
CA2691529C (en) 2016-01-05
EP2185555B1 (en) 2016-03-16
DOP2009000291A (es) 2010-01-31
WO2009019286A1 (en) 2009-02-12
JP2010535739A (ja) 2010-11-25
US20100292271A1 (en) 2010-11-18
CA2691529A1 (en) 2009-02-12
ZA200909075B (en) 2013-03-27
MX2009013956A (es) 2010-04-30
TW200914453A (en) 2009-04-01
KR20100039300A (ko) 2010-04-15
AU2008285652B2 (en) 2013-09-05
NZ581986A (en) 2012-02-24

Similar Documents

Publication Publication Date Title
HK1143588A1 (zh) 適合用於治療對血清素 受體調節有反應的病症的多種喹啉化合物
IL266471A (en) Apoptosis modulators with controlled release and methods for treating ear-related disorders
IL241791A0 (en) Historical use of 3,1-diphenylprop-2-en-1-one for the treatment of liver disorders
IL201107A0 (en) Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
PL2364142T3 (pl) Kompozycje modulatora receptora 5-HT<sub>2A</sub> serotoniny przydatne do leczenia związanych z nim zaburzeń
HK1163104A1 (zh) 適合治療對調節血清素 受體應答的病症的 -苯基- 哌嗪基或高哌嗪基 -苯磺酰胺或苯磺酰基-苯基- 哌嗪或高哌嗪 化合物
PT2229369T (pt) Derivados de 6,7-dialcoxi-quinazolina úteis para tratamento de distúrbios relacionados com o cancro
HK1139933A1 (en) Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
ZA201007325B (en) Azaindole compounds for treatment of central nervous system disorders
ZA200703059B (en) 6-Amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
IL225745A (en) Converted aromatic compounds arylsulfonylmethyl or arylsulfonamide suitable for the treatment of disorders responsive to the regulation of dopamine 3d receptor
ZA200705008B (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
EP2533780A4 (en) 5-HT4 RECEPTOR AGONISTS FOR THE TREATMENT OF DEMENTIA
HK1146628A1 (en) 1,2,4,-triazin-3,5-dione compounds for treating disorders that respond to modulation of the dopamine d3 receptor
ZA201003594B (en) Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
EP2578206A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISORDERS OF THE LOWER PART OF THE UROGENITAL SYSTEM
EP2240460A4 (en) BRANCHED DIEPXYDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200806